Stockreport

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Lineage Cell Therapeutics, Inc.  (LCTX) 
PDF Advanced OpRegen® For Dry AMD in Phase 2a Study in Collaboration with Roche and GenentechClosed $14 Million Registered Direct OfferingOPC1 Investigational New Drug Amend [Read more]